Milestone Influenza Publication by Elsevier Journal Vaccine
Supplement launched at successful Influenza Conference
Amsterdam, October 14, 2008 – Last month during an influenza conference organized by the European Scientific Working Group on influenza (ESWI), the Elsevier journal Vaccine released a supplement dedicated to influenza vaccines. This publication provides a comprehensive, state-of-the-art overview on influenza vaccines and was supported by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
Influenza, commonly known as (the) Flu, continues to be a major cause of mortality, and vaccination remains the mainstay of efforts to prevent and control the disease. Flu spreads around the world in seasonal epidemics, killing millions of people in pandemic and hundreds of thousands in non-pandemic years.
In their editorial in the supplement, Marie Paule Kieny and Keiji Fukuda of the World Health Organization (WHO) specifically address the pandemic influenza vaccine challenge and stress: ”that an efficient response at the outset of an influenza pandemic will depend on the robust global surveillance systems implemented by the WHO’s Global Influenza Surveillance Network”.
The Vaccine supplement focuses entirely on new developments in the area of human influenza vaccines, by bringing together key experts from many of the relevant disciplines in this field. “It is a highly valuable and very timely publication and I am convinced that it will be well-read across the world” stated Co-Guest Editor Gregory Poland, from the Mayo Clinic College of Medicine in Rochester, USA.
The 3rd European Influenza Conference in Portugal was organized by ESWI and had a scientific program including every aspect of influenza prevention, control and treatment. Beyond the science, the conference also offered sessions and workshops for governmental representatives and opinion leaders in healthcare. ESWI President and Co-Guest Editor of the Vaccine supplement Ab Osterhaus, from the Erasmus Medical Centre in Rotterdam, the Netherlands, considered the meeting a great success and said: “Communication and cooperation between scientists, policy makers and healthcare professionals is key to significantly reducing the burden of influenza, and the conference facilitated that process perfectly”.
Notes to editors:
To receive a copy of Vaccine Volume 26, Supplement 4; Influenza Vaccines: Research, Development and Public Health challenges (Guest editors: A.D.M.E. Osterhaus and G.A. Poland), please contact the press office at email@example.com.
The European Scientific Working Group on Influenza (ESWI) brings together influenza experts of different disciplines from all over Europe, in the aim to combat the impact of epidemic and pandemic influenza. ESWI communicates with all influenza stakeholders and facilitates interactions among them. The organization of the European influenza conferences (ESWI conferences) is a crucial means to realize this ambition.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Floris de Hon
+31 (0) 20 485 2498